List of Pulse by NABP Customers
Prospect, 60056, IL,
United States
Since 2010, our global team of researchers has been studying Pulse by NABP customers around the world, aggregating massive amounts of data points that form the basis of our forecast assumptions and perhaps the rise and fall of certain vendors and their products on a quarterly basis.
Each quarter our research team identifies companies that have purchased Pulse by NABP for Blockchain Platform from public (Press Releases, Customer References, Testimonials, Case Studies and Success Stories) and proprietary sources, including the customer size, industry, location, implementation status, partner involvement, LOB Key Stakeholders and related IT decision-makers contact details.
Companies using Pulse by NABP for Blockchain Platform include: CVS, a United States based Healthcare organisation with 300000 employees and revenues of $378.96 billion, McKesson, a United States based Distribution organisation with 45000 employees and revenues of $359.10 billion, Pfizer, a United States based Life Sciences organisation with 81000 employees and revenues of $63.63 billion, The National Association of Boards of Pharmacy (NABP), a United States based Non Profit organisation with 300 employees and revenues of $35.0 million and many others.
Contact us if you need a completed and verified list of companies using Pulse by NABP, including the breakdown by industry (21 Verticals), Geography (Region, Country, State, City), Company Size (Revenue, Employees, Asset) and related IT Decision Makers, Key Stakeholders, business and technology executives responsible for the software purchases.
The Pulse by NABP customer wins are being incorporated in our Enterprise Applications Buyer Insight and Technographics Customer Database which has over 100 data fields that detail company usage of software systems and their digital transformation initiatives. Apps Run The World wants to become your No. 1 technographic data source!
Apply Filters For Customers
| Logo | Customer | Industry | Empl. | Revenue | Country | Vendor | Application | Category | When | SI | Insight |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
CVS | Healthcare | 300000 | $379.0B | United States | The National Association of Boards of Pharmacy (NABP) | Pulse by NABP | Blockchain Platform | 2022 | n/a |
In 2022 CVS Health participated in Pulse by NABP as part of Pulse’s 2022–2023 pilot program, deploying Pulse by NABP to support Drug Supply Chain Security Act compliance across its U.S. pharmacy supply chain. The engagement centered on using a Blockchain Platform to improve product tracing and verification, increasing visibility for regulators and trading partners along distribution and dispensing workflows.
The implementation emphasized product verification and product tracing capabilities within Pulse by NABP, leveraging distributed ledger concepts typical of a Blockchain Platform to create an immutable audit trail and serialized item-level traceability. Functional workflows aligned to DSCSA included verification of drug provenance, chain of custody recording, and trading partner attestations, with Pulse by NABP serving as the system of record for those trace events.
Operational coverage focused on CVS Health’s U.S. pharmacy supply chain, connecting pharmacy sites, upstream distributors, and regulatory reporting channels to provide shared visibility for trading partners and regulators. The public notes for the pilot indicate this visibility outcome, and the specific use of product verification and tracing features is inferred from the pilot descriptions and Pulse documentation.
Governance was exercised through the structured pilot participation during 2022 and into 2023, with rollout scoped as pilot program activity rather than broad enterprise production deployment. Pulse by NABP as a Blockchain Platform was positioned to enable standardized verification workflows and cross‑stakeholder data sharing to support DSCSA obligations, while remaining within the pilot governance and evaluation framework.
|
 |
McKesson | Distribution | 45000 | $359.1B | United States | The National Association of Boards of Pharmacy (NABP) | Pulse by NABP | Blockchain Platform | 2022 | n/a |
In 2022, McKesson participated in a pilot of Pulse by NABP, a Blockchain Platform, to validate traceability and authorized trading partner verification under DSCSA requirements. The pilot participation was disclosed by the platform owner and targeted distributor and wholesaler operations in the United States.
Pulse by NABP was exercised in the pilot for product verification and tracing capabilities, aligning with serialization and traceability workflows typical of a Blockchain Platform. Functional emphasis inferred from the platform’s stated capabilities includes recording product provenance events, exchanging transaction level serialization data, and verifying trading partner credentials to support DSCSA interoperability. The implementation signal points to configuration around permissioned ledger access and identity attestations to enable cross partner verification.
Operational coverage focused on wholesale distribution and distributor nodes where McKesson participated as a trading partner node within the pilot network, concentrating on cross enterprise message exchange for verification and tracing. Integrations are described generically in category aligned terms, with expected data feeds for product serialization and order level events feeding the Pulse by NABP ledger, although specific upstream system names were not provided.
Governance in the pilot emphasized authorized trading partner verification processes and cross organization data sharing controls, with onboarding workflows to attest partner permissions and allow selective visibility of trace events. The record of McKesson participation comes from Pulse by NABP pilot disclosures and the precise module usage such as product verification and tracing is inferred from the Pulse by NABP platform capabilities.
|
 |
Pfizer | Life Sciences | 81000 | $63.6B | United States | The National Association of Boards of Pharmacy (NABP) | Pulse by NABP | Blockchain Platform | 2022 | n/a |
In 2022, Pfizer participated as a Pulse by NABP pilot participant to test product tracing, authorized trading partner verification, and interoperability features supporting DSCSA implementation in the United States. Pfizer engaged with Pulse by NABP, a Blockchain Platform, to exercise product verification and tracing functionality documented in Pulse and NABP pilot materials.
Pilot workstreams focused on distributed ledger based product tracing, authorized trading partner identity verification, and interoperability for exchanging serialized product event data. Functional capabilities exercised included product tracing, authorized trading partner verification, and cross‑participant interoperability, with workflows aligned to immutable event recording, provenance tracking, and identity attestation typical of a Blockchain Platform.
The operational scope targeted US DSCSA compliance use cases, spanning supply chain and regulatory compliance teams within Pfizer and involving pilot governance and test case contributions documented in the Pulse/NABP pilot materials. The engagement centered on validating platform interoperability and product verification workflows rather than full production rollout, with implementation details and feature usage inferred from pilot descriptions and platform capabilities.
|
 |
|
Non Profit | 300 | $35M | United States | The National Association of Boards of Pharmacy (NABP) | Pulse by NABP | Blockchain Platform | 2020 | Ibm |
|
Buyer Intent: Companies Evaluating Pulse by NABP
Discover Software Buyers actively Evaluating Enterprise Applications
| Logo | Company | Industry | Employees | Revenue | Country | Evaluated | ||
|---|---|---|---|---|---|---|---|---|
| No data found | ||||||||